UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048528
Receipt number R000055283
Scientific Title Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes
Date of disclosure of the study information 2022/08/04
Last modified on 2022/07/31 17:58:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Acronym

Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Scientific Title

Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Scientific Title:Acronym

Efficacy and quality of life changes in switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes

Region

Japan


Condition

Condition

type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate changes in Time in range and quality of life by switching traditional rapid acting insulin to ultra rapid Lispro in patients with type 2 diabetes.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in Time in range from Freestyle Libre Pro data and ITR-QOL score by switching traditional rapid acting insulin to ultra rapid Lispro.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Have patients fill out the insulin selection sheet. Patients who are judged to be more suitable for ultra rapid Lispro and who wish to change to it are required to answer the questionnaire (Insulin Therapy Related Quality-of-life Measure:ITR-QOL).Attach continuous blood glucose monitoring (Freestyle Libre Pro) for 14 days to patients who started using ultra rapid Lispro.


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Type 2 diabetes patients who have been treated with traditional rapid acting fast-acting insulin for more than 6 months before the study
2) Patients who are judged to be more suitable for ultra rapid Lispro from the insulin selection sheet

Key exclusion criteria

1) Patients allergic to insulin lispro
2) Patients who cannot administer ultra rapid Lispro within 2 minutes before meals and within 20 minutes from the start of meals when necessary.

Target sample size

15


Research contact person

Name of lead principal investigator

1st name Yuriko
Middle name
Last name Hajika

Organization

Minami Osaka Hospital

Division name

Internal Medicine

Zip code

559-0012

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, Japan

TEL

06-6685-0221

Email

y.hajika@minamiosaka.com


Public contact

Name of contact person

1st name Yuriko
Middle name
Last name Hajika

Organization

Minami Osaka Hospital

Division name

Internal Medicine

Zip code

559-0012

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, Japan

TEL

06-6685-0221

Homepage URL


Email

y.hajika@minamiosaka.com


Sponsor or person

Institute

Minami Osaka Hospital
Internal Medicine

Institute

Department

Personal name



Funding Source

Organization

nothing

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Minami Osaka Hospital

Address

1-18-18, Higashikagaya, Suminoe-ku, Osaka, Japan

Tel

06-6685-0221

Email

y.hajika@minamiosaka.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2022 Year 07 Month 20 Day

Date of IRB


Anticipated trial start date

2022 Year 08 Month 04 Day

Last follow-up date

2023 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 07 Month 31 Day

Last modified on

2022 Year 07 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055283


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name